The Vienna Prograf and Endothelial Progenitor Cell Study

Trial Profile

The Vienna Prograf and Endothelial Progenitor Cell Study

Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Apr 2014

At a glance

  • Drugs Tacrolimus (Primary) ; Ciclosporin
  • Indications Renal transplant rejection
  • Focus Biomarker; Pharmacodynamics
  • Acronyms Vienna-PEP-Study
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 04 May 2013 New source identified and integrated (European Clinical Trials Database record: EudraCT2004-004209-98).
    • 18 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top